TMDX: financial statements from SEC — TradeAlmanac

TMDX

TransMedics Group, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024
Revenue	605m	442m
Cost of revenue	243m	179m
Gross profit	363m	262m
Research and development	69m	56m
Selling, general and administrative	185m	169m
Operating expenses	254m	225m
Operating income	109m	37m
Pre-tax income	108m	36m
Income tax	−83m	316,000
Net income	190m	35m
Earnings per share	5.60	1.07
Earnings per share, diluted	4.87	1.01
Weighted average shares	34m	33m
Weighted average shares, diluted	41m	35m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	480m	489m	467m	401m	311m	337m	331m	363m
Receivables	91m	84m	81m

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024
Operating cash flow	193m	49m
Depreciation and amortisation	27m	20m
Share-based compensation	37m	33m
Capital expenditure	59m	130m
Investing cash flow	−59m	−129m
Financing cash flow	17m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)